Simon Keely
School of Biomedical Sciences and Pharmacy
Newcastle University
Australia
Biography
Dr. Keely graduated with a Ph.D. from University College Dublin. He undertook postdoctoral research training at the Mucosal Inflammation Program in University of Colorado Denver before being promoted to junior faculty positions (Instructor and Senior Instructor) in the School of Medicine and receiving a prestigious fellowship from the Crohn's and Colitis Foundation of America. Dr. Keely is chief investigator of the Hunter Medical Research Institute (HMRI) Gastrointestinal Research Group. The group's current research examines molecular mechanisms of disease in the gastrointestinal tract. Dr. Keely is particularly interested in how the mucosal tissues function and repair with reduced oxygen availability during inflammation. Dr. Keely is also interested in the changes that occur with microbial interactions during inflammation and how these interactions influence the progression and resolution of mucosal diseases. The ultimate goal of this research is understanding how these factors may be pharmacologically manipulated for therapeutic benefit.
Research Interest
Biochemistry and Cell Biology, Gastroenterology and Hepatology, Immunology
Publications
-
Marks E, Naudin C, Nolan G, Goggins BJ, Burns G, Mateer SW, Latimore JK, Minahan K, Plank M, Foster PS, Callister R. Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation. Mucosal immunology. 2017 Jan 25.
-
Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory.
-
Marks E, Goggins BJ, Cardona J, Cole S, Minahan K, Mateer S, Walker MM, Shalwitz R, Keely S. Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis. Inflammatory bowel diseases. 2015 Feb 1;21(2):267-75.
